The Russian Direct Investment Fund (RDIF) and Dr Reddy’s Laboratories Limited, a global pharmaceutical company headquartered in India, have agreed to cooperate on clinical trials and distribution of Sputnik V COVID-19 vaccine in India.
“Indian trials of the Sputnik-V vaccine candidate, being developed by Russia’s sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals across the country.
“We want to get to the first step – which is the commencement of the clinical trials by getting the necessary approvals from the Indian regulators – within the next few weeks,” Deepak Sapra, CEO for API and pharmaceutical services at Dr Reddy’s, told Reuters.
Sapra added that they will identify potential manufacturers in India. The vaccine will have the inputs of both the Indian as well as Russian company.